Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | VT1021 |
Synonyms | |
Therapy Description |
VT1021 is a cyclic pentapeptide that induces thrombospondin-1 expression in the tumor microenvironment, which may lead to enhanced anti-tumor immune response (J Clin Oncol 37, 2019 (suppl; abstr TPS3158). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
VT1021 | VT-1021|VT 1021 | VT1021 is a cyclic pentapeptide that induces thrombospondin-1 expression in the tumor microenvironment, which may lead to enhanced anti-tumor immune response (J Clin Oncol 37, 2019 (suppl; abstr TPS3158). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03364400 | Phase I | VT1021 | Phase 1 Study Evaluating VT1021 in Patients With Advanced Solid Tumors | Active, not recruiting | USA | 0 |